Actavis builds antibiotic presence with $675m+ Durata deal

Antibiotic developer Durata Therapeutics saw its share price rocket by up to 75% after Actavis announced a deal to acquire the Nasdaq-listed firm. Its shares rose from Friday's close of $13.88 to upwards of $24.30 during trading on Monday.